Resources
for You and Your Team

What is the CMS ASPIRE Model? A 10-Year Value-Based Care Roadmap for Digital Health
Articles Sam Pinson and Cyndi Baily Articles Sam Pinson and Cyndi Baily

What is the CMS ASPIRE Model? A 10-Year Value-Based Care Roadmap for Digital Health

The CMS ASPIRE Model (Accelerating State Pediatric Innovation Readiness and Effectiveness) is a landmark 10-year initiative launched in 2026 to transform pediatric care for Medicaid and CHIP beneficiaries. By moving from Fee-For-Service to a Value-Based Care (VBC) framework, ASPIRE incentivizes "whole-person" health for youth up to age 21. For digital health innovators, the model creates a critical demand for interoperable care management, AI-driven risk stratification, and unified care plans that bridge clinical, school, and home environments.

Read More
New CMS & FDA Innovation Models: What ACCESS, TEMPO, and MAHA ELEVATE Mean for Digital Health Innovators
Videos Nixon Law Group Videos Nixon Law Group

New CMS & FDA Innovation Models: What ACCESS, TEMPO, and MAHA ELEVATE Mean for Digital Health Innovators

CMS and FDA introduced ACCESS, TEMPO, and MAHA ELEVATE, three major innovation models that signal a shift in how federal agencies are thinking about digital health, care management, and reimbursement. In this webinar, Nixon Law Group’s attorneys break down what each model does, what types of entities can participate, and where we see concrete opportunities for digital health companies to engage.

Read More
Women’s Health & FemTech in 2026: 5 Compliance Pillars for Founders
Articles Reema Taneja Articles Reema Taneja

Women’s Health & FemTech in 2026: 5 Compliance Pillars for Founders

In 2026, compliance is a competitive advantage in women’s health and FemTech. This article breaks down five critical pillars founders must address—from reproductive data privacy and FDA regulation to AI governance, corporate practice of medicine, and intellectual property strategy—to build trust, attract investment, and scale responsibly.

Read More
CMS Announces MAHA ELEVATE Model: A New Opportunity to Shape Reimbursement for Lifestyle, Functional, and Whole-Person Care Services
Articles Carrie Nixon and Olivia Rothstein Articles Carrie Nixon and Olivia Rothstein

CMS Announces MAHA ELEVATE Model: A New Opportunity to Shape Reimbursement for Lifestyle, Functional, and Whole-Person Care Services

CMS’s new MAHA ELEVATE Model offers $100M in funding to evaluate evidence-based lifestyle, functional, and whole-person care interventions not currently covered by Medicare. Launching in 2026, this initiative creates a pathway for healthcare innovators, digital health companies, and care organizations to influence future Medicare coverage and reimbursement for chronic disease prevention and management.

Read More
FDA Launches TEMPO: What Digital Health Innovators Need to Know Now
Articles Carrie Nixon and Michael Schellhous Articles Carrie Nixon and Michael Schellhous

FDA Launches TEMPO: What Digital Health Innovators Need to Know Now

FDA’s new TEMPO pilot creates a flexible, real-world evidence pathway for digital health, SaMD, DTx, wearables, and AI-enabled devices—aligned with CMS’s ACCESS model. Learn how innovators can use enforcement discretion to deploy faster, collect RWD/RWE, and strengthen future FDA submissions.

Read More
Implementing a Privacy Program that Scales: Essential HIPAA Practices for Digital Health Companies
Articles Carrie Nixon and Olivia Rothstein Articles Carrie Nixon and Olivia Rothstein

Implementing a Privacy Program that Scales: Essential HIPAA Practices for Digital Health Companies

HIPAA compliance is more than encryption and security controls—it requires a scalable privacy program that matures as your digital health company grows. Learn how Privacy Risk Assessments, BAAs, staff training, and patient-rights workflows create a competitive advantage in today’s health tech landscape.

Read More
FDA Advisory Committee Signals New Regulatory Expectations for Generative AI in Digital Mental Health: What Innovators Need to Know Now
Articles Michael Schellhous and Sam Pinson Articles Michael Schellhous and Sam Pinson

FDA Advisory Committee Signals New Regulatory Expectations for Generative AI in Digital Mental Health: What Innovators Need to Know Now

On November 6, 2025, the FDA’s Digital Health Advisory Committee delivered a clear message to the generative AI DMH sector: expect greater structure and tighter oversight. This article breaks down the 6 key themes—including the need for a new risk taxonomy, model drift management, and clinician-supervised use—and provides 5 immediate actions developers, deployers, and investors must prioritize to navigate the evolving regulatory landscape.

Read More